Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Viruses ; 13(10)2021 10 04.
Article in English | MEDLINE | ID: covidwho-1463829

ABSTRACT

With the emerging success of the COVID-19 vaccination programs, the incidence of acute COVID-19 will decrease. However, given the high number of people who contracted SARS-CoV-2 infection and recovered, we will be faced with a significant number of patients with persistent symptoms even months after their COVID-19 infection. In this setting, long COVID and its cardiovascular manifestations, including pericarditis, need to become a top priority for healthcare systems as a new chronic disease process. Concerning the relationship between COVID-19 and pericardial diseases, pericarditis appears to be common in the acute infection but rare in the postacute period, while small pericardial effusions may be relatively common in the postacute period of COVID-19. Here, we reported a series of 7 patients developing pericarditis after a median of 20 days from clinical and virological recovery from SARS-CoV-2 infection. We excluded specific identifiable causes of pericarditis, hence we speculate that these cases can be contextualized within the clinical spectrum of long COVID. All our patients were treated with a combination of colchicine and either ASA or NSAIDs, but four of them did not achieve a clinical response. When switched to glucocorticoids, these four patients recovered with no recurrence during drug tapering. Based on this observation and on the latency of pericarditis occurrence (a median of 20 days after a negative nasopharyngeal swab), could be suggested that post-COVID pericarditis may be linked to ongoing inflammation sustained by the persistence of viral nucleic acid without virus replication in the pericardium. Therefore, glucocorticoids may be a suitable treatment option in patients not responding or intolerant to conventional therapy and who require to counteract the pericardial inflammatory component rather than direct an acute viral injury to the pericardial tissue.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , COVID-19/complications , Glucocorticoids/therapeutic use , Pericarditis/drug therapy , Aged , COVID-19/pathology , Colchicine/therapeutic use , Female , Humans , Male , Middle Aged , Pericardial Effusion/pathology , Pericarditis/pathology , Pericarditis/virology , Pericardium/pathology , Pericardium/virology , SARS-CoV-2 , Post-Acute COVID-19 Syndrome , COVID-19 Drug Treatment
2.
Inflammation ; 45(1): 1-5, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1415062

ABSTRACT

Novel Coronavirus Disease in most cases produces mild symptoms which resolve after a few days. Some authors hypothesized that SARS-CoV-2 infection could trigger excessive cytokine production leading to a severe multi-organ disease requiring intensive care admission. Respiratory and neurological symptoms are the most frequently reported manifestation of the disease. Indeed, cardiac involvement is reported mostly as a part of a systemic disease. Few isolated cardiac manifestations of COVID-19 infection have been described. We report herein a case of SARS-CoV-2 related severe isolated pericardial involvement requiring ICU admission due to cardiac tamponade needing urgent drainage. Analysis of pericardial fluid from drainage demonstrated a higher cytokine concentration than blood values. Other causes of pericardial disease, such as autoimmunity, bacterial or other than COVID-19 infection, neoplasms or acute myocardial infarction were also evaluated, but all tests confirmed negative results. The suspicion of isolated involvement of the pericardium was therefore demonstrated by the analysis of cytokines which strongly support our hypothesis.


Subject(s)
COVID-19/pathology , Cardiac Tamponade/pathology , Cytokines/analysis , Pericardial Effusion/surgery , Pericardial Fluid/chemistry , Pericardium/pathology , Aged , Cardiac Tamponade/surgery , Cytokine Release Syndrome/pathology , Humans , Male , Pericardial Effusion/pathology , Pericardium/virology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL